April 4, 2017
Creso Pharma welcomes new COO
Creso Pharma has appointed pharmaceutical and biotech industry professional David Russell as its Chief Operating Officer.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 4, 2017
Galapagos in three new Phase 2 studies with filgotinib
Galapagos NV announced on Tuesday three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren`s syndrome, ankylosing spondylitis, and psoriatic arthritis.
April 4, 2017
Verona Pharma doses first patients in UK testing its cystic fibrosis candidate
Verona Pharma has dosed the first patient in a phase 2a test of its candidate RPL554 for cystic fibrosis, the most common fatal inherited disease in the United States and Europe.
April 4, 2017
FDA OK’s Teva’s Huntington’s disease drug
U.S. Food and Drug Administration (FDA) has approved Teva’s Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD).
April 4, 2017
Shield Therapeutics welcomes new financial boss to the Group
Shield Therapeutics will welcome new Chief Financial Officer to the Group, who will be a Board member, in the beginning of the month of May 2017.
April 3, 2017
FDA grants Kitov waiver for New Drug Application filing fee
Kitov Pharmaceuticals Holdings Ltd, a NASDAQ and TASE listed innovative biopharmaceutical company, said Monday that that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver related to the $2,038,100 New Drug Application filing fee for Kitov’s patented combination of …
April 3, 2017
Incyte, Bristol-Myers Squibb move epacadostat plus Opdivo combination into pivotal studies
Bristol-Myers Squibb and Incyte Corporation will evaluate combination of epacadostat with Opdivo in advancing a clinical development program into phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.
April 3, 2017
Novartis cleared for combining Tafinlar with Mekinist in Europe to treat certain cancer
Novartis has been cleared in Europe for Tafinlar combined with Mekinist (dabrafenib with trametinib) to treat patients with BRAF V600-with advanced non-small cell lung cancer (NSCLC).
April 3, 2017
Once-weekly semaglutide lowers blood glucose and weight with type 2 diabetes patients
Novo Nordisk said Monday that once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment.
April 3, 2017
Two new e-tailers for InnovaDerma’s products
InnovaDerma, a UK developer of life sciences, beauty and personal care products has secured new e-tailer distribution deals.